Skip to main content

Table 2 Association between PPARγ2 CG/GG genotype (Ala variant) and serum lipids in HIV/HCV coinfected patients

From: PPARγ2 Pro12Ala polymorphism was associated with favorable cardiometabolic risk profile in HIV/HCV coinfected patients: a cross-sectional study

 

CC

CG/GG

p-value(a)

aAMR (95% CI)

p-value(b)

TC (mg/dL)

156.0 (63.0)

139.0 (49.0)

0.008

0.87 (0.79; 0.95)

0.004

TG (mg/dL)

122.0 (49.0)

122.0 (27.0)

0.319

0.92 (0.81; 1.04)

0.163

LDL-C (mg/dL)

86.4 (54.1)

72.4 (36.0)

0.005

0.79 (0.68; 0.93)

0.004

HDL-C (mg/dL)

36.0 (18.0)

36.0 (12.0)

0.921

0.98 (0.89; 1.09)

0.734

LDL-C/HDL-C

2.1 (1.3)

1.8 (1.1)

0.027

0.86 (0.73; 1.01)

0.067

AI

2.7 (1.6)

2.5 (1.4)

0.031

0.87 (0.76; 1.01)

0.069

  1. Values expressed as median [interquartile range = upper quartile (Q3) - lower quartile (Q1)] and adjusted arithmetic mean ratio (aAMR) [95% of confidence interval (95% CI)]. Statistically significant differences are shown in bold. (a)P-values were calculated by generalized linear models (GLM) with gamma distribution (log-link). (b)P-values were calculated by GLM with log-link adjusted by the most important clinical and epidemiological characteristics (see Statistical analysis section).
  2. Abbreviations: HCV hepatitis C virus, HIV human immunodeficiency virus, TC total cholesterol, TG triglycerides, LDL-C low density lipoprotein, HDL-C high density lipoprotein, LDL-C/HDL-C ratio of low density lipoprotein/high density lipoprotein, AI atherogenic index.